CRISPR Gene Editing Global Market Report 2026

Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing is an advanced biotechnology technique that enables targeted and precise alterations to the DNA of living organisms. The technology is based on a natural bacterial defense mechanism in which CRISPR-associated DNA sequences help recognize and target particular genetic sequences for cutting. CRISPR gene editing can be used to insert, remove, or modify genetic material, making it an important tool for scientific research, therapeutic development, and the potential treatment of genetic disorders.

The primary types of CRISPR gene editing include CRISPR-associated nuclease (cas nuclease), guide ribonucleic acid (RNA), deoxyribonucleic acid (DNA) ligase, restriction endonuclease, and others. CRISPR-associated nuclease, also known as Cas Nuclease, is a protein that acts as molecular scissors by cutting specific DNA sequences identified and targeted by CRISPR. This segment covers the development and application of Cas proteins for accurate gene editing, with potential uses across agriculture, medicine, and biotechnology. The offerings include design tools, plasmid and vector, CRISPR-associated protein 9 (cas9) and guide ribonucleic acid (g-RNA), delivery system products, and others. The technologies include clustered regularly interspaced short palindromic repeats CRISPR or cas9, zinc finger nucleases, and others, supporting applications such as agricultural, biomedical, industrial, genome engineering, disease models, functional genomics, and others. These products and services are utilized by academic institutes and research centers, biotechnology companies, contract research organizations (CROS), and pharmaceutical and biopharmaceutical companies.

Tariffs are influencing the crispr gene editing market by raising the costs of imported reagents, delivery systems, plasmids, and laboratory equipment. Research institutions and biotechnology companies in North America and Europe are experiencing greater cost pressure due to their dependence on imported inputs, while Asia-Pacific is facing increased expenses for acquiring advanced technologies. These tariffs are increasing research and development expenditures. However, they are also encouraging domestic biotechnology manufacturing and strengthening regional innovation capabilities.

The CRISPR gene editing market research report is one of a series of new reports from The Business Research Company that provides CRISPR gene editing market statistics, including CRISPR gene editing industry global market size, regional shares, competitors with a CRISPR gene editing market share, detailed CRISPR gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR gene editing industry. This CRISPR gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The crispr gene editing market size has grown rapidly in recent years. It will grow from $4.03 billion in 2025 to $4.7 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing demand for accurate gene modification technologies, limitations associated with earlier gene editing methods, expansion of genomics research, growing adoption within academic institutions, and increased funding for genetic research.

The crispr gene editing market size is expected to see rapid growth in the next few years. It will grow to $8.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to increasing approvals of gene editing therapies, continued expansion of precision medicine applications, growth of agricultural biotechnology, development of supportive regulatory frameworks, and ongoing technological improvements in CRISPR systems. Major trends in the forecast period include increasing clinical research in gene therapy, expansion of gene editing applications in agriculture, growing adoption of functional genomics research, continued advancements in gene delivery technologies, and increasing emphasis on ethical considerations and regulatory compliance.

The increasing prevalence of genetic disorders is anticipated to support the growth of the CRISPR gene editing market in the coming years. Genetic disorders are medical conditions resulting from abnormalities in the genome, including mutations affecting a single gene (monogenic), several genes (polygenic), or chromosomes. The prevalence of genetic disorders is rising because of genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays an important role in addressing genetic disorders by enabling accurate and targeted changes to DNA. Moreover, researchers utilize CRISPR technology to detect and repair specific mutations responsible for genetic disorders, restore normal biological functions, and reduce disease symptoms, as demonstrated in conditions such as cystic fibrosis and sickle cell anaemia. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity focused on supporting individuals affected by cystic fibrosis, 164 new cases of cystic fibrosis (CF) were diagnosed in 2024, of which 123 were detected through newborn screening. At the end of 2024, 11,381 individuals were registered with CF. Therefore, the growing prevalence of genetic disorders is contributing to the expansion of the CRISPR gene editing market.

Key companies operating in the CRISPR gene editing market are focusing on developing innovative products such as gene therapy to reach a larger customer base, increase sales, and enhance revenue. Gene therapy is a medical technique that uses genes to treat, prevent, or cure diseases and disorders. For example, in December 2023, the US Food and Drug Administration (FDA), a US-based federal agency, approved Casgevy, a cell-based gene therapy, for the treatment of sickle cell disease. Casgevy therapy utilizes CRISPR/Cas9, a type of genome editing technology. Hematopoietic stem cells are modified using CRISPR/Cas9 technology.

In April 2024, Cellistic, a Belgium-based cell therapy platform provider, acquired Artisan Bio for an undisclosed amount. Through this acquisition, Cellistic sought to strengthen its gene and cell therapy development capabilities by incorporating Artisan Bio's STAR-CRISPR Cas-12 gene-editing platform, enabling more precise genome modifications and supporting the development of advanced engineered cell therapy solutions. Artisan Bio is a US-based biotechnology company specializing in next-generation CRISPR gene-editing technologies.

Major companies operating in the crispr gene editing market are Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated DNA Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., Churchi Genome Engineering and Therapeutic Research Center, Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

North America was the largest region in the CRISPR gene editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr gene editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the crispr gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CRISPR Gene Editing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses crispr gene editing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for crispr gene editing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crispr gene editing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: CRISPR-Associated Nuclease (Cas Nuclease); Guide Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA) Ligase; Restriction Endonuclease; Other Types
• 2) By Services: Design Tools; Plasmid And Vector; CRISPR-Associated Protein 9 (Cas9) And Guide Ribonucleic Acid (g-RNA); Delivery System Products; Other Services
• 3) By Technology: CRISPR Or Cas9; Zinc Finger Nucleases; Other Technologies
• 4) By Application: Agricultural; Biomedical; Industrial; Genome Engineering; Disease Models; Functional Genomics; Other Applications
• 5) By End User: Academic Institutes And Research Centers; Biotechnology Companies; Contract Research Organizations (CROs); Pharmaceutical And Biopharmaceutical Companies
• Subsegments:
• 1) By CRISPR-Associated Nuclease (Cas Nuclease): Cas9; Cas12; Cas13
• 2) By Guide Ribonucleic Acid (RNA): Single-Guide RNA (sgRNA); Dual-Guide RNA; Synthetic Guide RNA
• 3) By Deoxyribonucleic Acid (DNA) Ligase: T4 DNA Ligase; E. Coli DNA Ligase
• 4) By Restriction Endonuclease: Type II Restriction Enzymes; Type I And III Restriction Enzymes
• 5) By Other Types: CRISPR Delivery Systems; CRISPR Plasmids; CRISPR-Based Diagnostic Tools
• Companies Mentioned: Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation; Integrated DNA Technology (Danaher); Editas Medicine; GenScript; Agilent Technologies; New England Biolabs; CSIR-Institute of Genomics & Integrative Biology (IGIB); Strand Life Sciences Pvt. Ltd.; Bio Palette Co. Ltd.; Churchi Genome Engineering and Therapeutic Research Center; Beam Therapeutics Inc.; Eurofins Genomics India; Setsurotech Co. Ltd.; Merck Japan; Institut Pasteur; CureVac; Cellectis; BiovelocITA S.r.l.; Evotec A.G.; SNIPR Biome; Oxford Genetics; ERS Genomics; Alia Therapeutics; Solvo; BioTalentum; BIOCAD; BioVendor; Research & Diagnostic Products; Contipro; Lonza Biotec; Sotio; Selvita; BioVentures Institute Ltd; Sigma-Aldrich; Poseida Therapeutics; NanoCellect Biomedical; Sherlock Biosciences; Repare Therapeutics; Inscripta Inc.; Santa Cruz Biotechnology; Caribou Biosciences Inc.; Egenesis Inc.; Homology Medicines; System Biosciences; Takara Bio USA Inc.; Inari Agriculture Inc.; Precision BioSciences; Cell Microsystems Inc.; GeneCopoeia Inc.; Merck KGaA; Origene Technologies Inc.; Pluristem Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.